Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.6M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
26.4M
-
Shares change
-
+2.23M
-
Total reported value, excl. options
-
$175M
-
Value change
-
+$10.1M
-
Put/Call ratio
-
1.62
-
Number of buys
-
50
-
Number of sells
-
-38
-
Price
-
$6.65
Significant Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q2 2021
107 filings reported holding CRDF - Cardiff Oncology, Inc. - Common Stock as of Q2 2021.
Cardiff Oncology, Inc. - Common Stock (CRDF) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.4M shares
of 66.6M outstanding shares and own 39.6% of the company stock.
Largest 10 shareholders include EVENTIDE ASSET MANAGEMENT, LLC (3.58M shares), JANUS HENDERSON GROUP PLC (3.15M shares), BlackRock Inc. (2.36M shares), CAXTON CORP (2.34M shares), VANGUARD GROUP INC (1.65M shares), Avidity Partners Management LP (1.4M shares), Corriente Advisors, LLC (1.38M shares), CITADEL ADVISORS LLC (1.18M shares), Octagon Capital Advisors LP (983K shares), and Artal Group S.A. (750K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.